Mineralys Therapeutics (MLYS) closed at $15.81 on November 9, 2026, up 3.1% from the previous close, on volume of 2,853,914 shares (30-day average 1,641,357).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Call Spread | 16-Apr-2735 : 45 C | 2,004 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 2:20 PM ET)
Globe Newswire (Sun, 8-Nov 4:35 PM ET)
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Wells Fargo
TipRanks (Fri, 6-Nov 9:24 AM ET)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 8:00 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Thu, 5-Nov 6:10 PM ET)
TipRanks (Thu, 5-Nov 9:02 AM ET)
Stifel Nicolaus Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TipRanks (Thu, 5-Nov 7:57 AM ET)
H.C. Wainwright Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
TipRanks (Thu, 5-Nov 6:36 AM ET)
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 3-Nov 4:05 PM ET)
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.
As of November 10, 2026, MLYS stock price declined to $15.58 with 20,437 million shares trading.
MLYS has a beta of 2.41, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.28 to the broad based SPY ETF.
MLYS has a market cap of $1.38 billion. This is considered a Small Cap stock.
In the last 3 years, MLYS traded as high as $47.65 and as low as $5.85.
The top ETF exchange traded funds that MLYS belongs to (by Net Assets): VTI, IWM, XBI, VXF, VTWO.
MLYS has underperformed the market in the last year with a price return of -59.0% while the SPY ETF gained +12.7%. MLYS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.0% and -24.2%, respectively, while the SPY returned -3.0% and -2.2%, respectively.
MLYS support price is $15.09 and resistance is $16.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.
